Recent Advances in Creating New Neural Pathways for Spinal Cord Injury

On a recent Price of Business show, Host Kevin Price visited with Paul Brennan who is NervGen CEO.

The two discussed the progress the treatment is making towards approval, which now includes human trials.

According to a statement, “Each year, around 250,000 to 500,000 people around the world suffer a spinal cord injury (SCI). The race to reverse paralysis is in full throttle with Northwestern University’s new study that describes an injection of dancing molecules to reverse paralysis in mice and repair tissues after severe spinal cord injuries and injured animals regaining the ability to walk four weeks after the injection.”Another university making great strides with SCI is Case Western Reserve led by Dr. Jerry Silver, a renowned spinal cord injury and regenerative medicine researcher and professor, with a blockbuster drug candidate NVG-291 – that is being developed with NervGen Pharma Corp a publicly traded clinical stage biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.

“NVG-291 is a peptide (a small protein) that works by targeting the protein tyrosine phosphatase sigma (PTP) receptor that blocks nerve repair following injury, whether from trauma or conditions such as spinal cord injury, multiple sclerosis and Alzheimer’s disease, says Dr. Silver. The drug targets nerve cell repair, while promoting plasticity to create new neural pathways.

“Here’s a link to a video<https://youtu.be/6izWmtJDkVs>; showing the rodents treated by NVG-291.”Dr. Silver has been tirelessly devoted to researching nerve regeneration for decades as reported in The New York Times article entitled, Rat Nerves Repaired and Rejoined with Spine in the 1980’s, which chronicles the first time crushed nerves were repaired.

“Today, with Phase 1 clinical trials already underway, NervGen Pharma says it’s on-track to become a big breakthrough thanks to its blockbuster drug candidate NVG-291 which goes into Phase 2 clinical trials with SCI patients next year.

“NervGen’s President & CEO, Paul Brennan, said, ‘We are excited and proud to be moving our therapy into clinical trials next year, not only for SCI, but also for multiple sclerosis and Alzheimer’s disease.’

“A new video<https://www.youtube.com/watch?v=NGWhkDI7woI>; from Case Western Reserve University School of Medicine/The Council to Advance Human Health offers insight into the development of the drug.”

RELATED:

NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial